Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS180

Li,Xiao‑Yun; Liao,Xiao‑Feng; Wang,Hong‑Bo; Zhang,Jian

doi:10.3892/ol.2018.9360

Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS180

Authors:
- Xiao‑Yun Li
- Xiao‑Feng Liao
- Hong‑Bo Wang
- Jian Zhang
View Affiliations

Affiliations: Department of General Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei College of Arts and Science, Xiangyang, Hubei 441021, P.R. China
Published online on: August 23, 2018 https://doi.org/10.3892/ol.2018.9360
Pages: 5923-5929
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite improvements in the development of drugs for the treatment of cancer, drug resistance remains a major obstacle. In colon cancer, following an initially promising response,, patients develop drug resistance, which impacts the efficacy and halts the response of cancerous cells towards drugs. In the present study, a phosphatase and tensin homolog (PTEN) knockdown model of LS180 cells, doxorubicin‑resistant models of LS180 cells as well as doxorubicin‑resistant LS180 (PTEN) knockdown model were established. The present study demonstrated that doxorubicin resistance led to the activation of interleukin (IL)6 signalling pathway which was enhanced by knockdown of PTEN. There was also an increase in the levels of IL8 and IL2 which were further enchanced by knockdown of PTEN. Doxorubicin resistance also led to an increase in the population of cancer stem cells in LS180 and shPTEN‑treated LS180 cells. Notably, doxorubicin resistance also induced epithelial to mesenchymal transition and increased the formation of mammospheres. Furthermore, the present study also reported that IL6 receptor antibody not only decreased IL6 levels but also led to a significant decreased number of cancer stem cell like population and mammosphere formation. In conclusion, in the present study it was demonstrated that doxorubicin resistance led to activation of IL6 signalling pathway which was further elevated by the knockdown of PTEN in the colon cancer cell line LS180. Thus, inhibiting the IL6 loop may provide an alternative pathway to tackle doxorubicin resistance.

View Figures

View References

1	Gandomani HS, Yousefi SM, Aghajani M, Mohammadian-Hafshejani A, Tarazoj AA, Pouyesh V and Salehiniya H: Colorectal cancer in the world: Incidence, mortality and risk factors. Biomed Res Therapy. 4:102017. View Article : Google Scholar
2	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mishra J, Dromund J, Quazi SH, Karanki SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013. View Article : Google Scholar : PubMed/NCBI
4	Wáng YX, De Baere T, Idée JM and Ballet S: Transcatheter embolization therapy in liver cancer: An update of clinical evidences. Chin J Cancer Res. 27:96–121. 2015.PubMed/NCBI
5	Blakely T, Collinson L, Kvizhinadze G, Nair N, Foster R, Dennett E and Sarfati D: Cancer care coordinators in stage III colon cancer: A cost-utility analysis. BMC Health Serv Res. 15:3062015. View Article : Google Scholar : PubMed/NCBI
6	Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M and McNeil BJ: Quality of care for older patients with cancer in the Veterans health administration versus the private sector: A cohort study. Ann Intern Med. 154:727–736. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lam TJ, Meurs-Szojda MM, Gundlach L, Belien JA, Meijer GA, Mulder CJ and Felt-Bersma RJ: There is no increased risk for colorectal cancer and adenomas in patients with diverticulitis: A retrospective longitudinal study. Colorectal Dis. 12:1122–1126. 2010. View Article : Google Scholar : PubMed/NCBI
8	Suraj R, Radhamani S, Meehan-Andrews T and Bradley C: Role of a novel benzoxazine derivative in the chemosensitization of colon cancer. Apoptosis. 22:988–1000. 2017. View Article : Google Scholar : PubMed/NCBI
9	Kadioglu O, Law BYK, Mok SWF, Xu SW, Efferth T and Wong VKW: Mode of action analyses of neferine, a bisbenzylisoquinoline alkaloid of lotus (Nelumbo nucifera) against multidrug-resistant tumor cells. Front Pharmacol. 8:2382017. View Article : Google Scholar : PubMed/NCBI
10	Kang XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q and Huang YZ: Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 38:885–896. 2017. View Article : Google Scholar : PubMed/NCBI
11	Xu J, Zhang S, Wang R, Wu X, Zeng L and Fu Z: Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Biosci Rep. 37:BSR201604472017. View Article : Google Scholar : PubMed/NCBI
12	Nedaeinia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M, Goli M, Piroozmand A, Nourmohammadi E, Manian M, et al: Current status and perspectives regarding LNA-Anti-miR oligonucleotides and microRNA miR-21 inhibitors as a potential therapeutic option in treatment of colorectal cancer. J Cell Biochem. 118:4129–4140. 2017. View Article : Google Scholar : PubMed/NCBI
13	Sambi M, Haq S, Samuel V, Qorri B, Haxho F, Hill K, Harless W and Szewczuk MR: Alternative therapies for metastatic breast cancer: Multimodal approach targeting tumor cell heterogeneity. Breast Cancer (Dove Med Press). 9:85–93. 2017.PubMed/NCBI
14	Schoumacher M and Burbridge M: Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr Oncol Rep. 19:192017. View Article : Google Scholar : PubMed/NCBI
15	Zheng D, Wu W, Dong N, Jiang X, Xu J, Zhan X, Zhang Z and Hu Z: Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene. Mol Carcinog. 56:2234–2244. 2017. View Article : Google Scholar : PubMed/NCBI
16	El Ouar I, Braicu C, Naimi D, Irimie A and Berindan-Neagoe I: Effect of Helix aspersa extract on TNFα, NF-κB and some tumor suppressor genes in breast cancer cell line Hs578T. Pharmacogn Mag. 13:281–285. 2017. View Article : Google Scholar : PubMed/NCBI
17	Mantamadiotis T: Towards targeting PI3K-dependent regulation of gene expression in brain cancer. Cancers (Basel). 9:E602017. View Article : Google Scholar : PubMed/NCBI
18	Ban HS, Kim BK, Kim HM, Harmalkar D, Nam M, Park SK, Lee K, Park JT, Kim I, et al: The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth. Cell Death Dis. 8:e28432017. View Article : Google Scholar : PubMed/NCBI
19	Tesio M, Trinquand A, Ballerini P, Hypolite G, Lhermitte L, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E and Asnafi V: Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. Leukemia. 31:2594–2600. 2017. View Article : Google Scholar : PubMed/NCBI
20	Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, Tang L, Hla T, Zeng R, Li L and Wu D: Regulation of PTEN by Rho small GTPases. Nat Cell Biol. 7:399–404. 2005. View Article : Google Scholar : PubMed/NCBI
21	Solari F, Bourbon-Piffaut A, Masse I, Payrastre B, Chan AM and Billaud M: The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans. Oncogene. 24:20–27. 2005. View Article : Google Scholar : PubMed/NCBI
22	Bar N and Dikstein R: miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
23	Chalhoub N and Baker SJ: PTEN and the PI3-Kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
24	Keniry M and Parsons R: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI
25	Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, et al: Activation of an IL-6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancers by expanding the cancer stem cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zarogoulidis P, Yarmus L, Darwiche K, Walter R, Huang H, Li Z, Zaric B, Tsakiridis K and Zarogoulidis K: Interleukin-6 cytokine: A multifunctional glycoprotein for cancer. Immunome Res. 9:165352013. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	El-Badawy A, Ghoneim MA, Gabr MM, Salah RA, Mohamed IK, Amer M and El-Badri N: Cancer cell-soluble factors reprogram mesenchymal stromal cells to slow cycling, chemoresistant cells with a more stem-like state. Stem Cell Res Ther. 8:2542017. View Article : Google Scholar : PubMed/NCBI
29	Hu T, Li Z, Gao CY and Cho CH: Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
30	Hammond WA, Swaika A and Mody K: Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
31	Pu H, Zheng Q, Li H, Wu M, An J, Gui X, Li T and Lu D: CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc. Oncotarget. 6:40775–40798. 2015. View Article : Google Scholar : PubMed/NCBI
32	Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C and Isidoro C: PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Oncotarget. 7:84999–85020. 2016. View Article : Google Scholar : PubMed/NCBI